Long-term efficacy and safety of elafibranor in primary biliary cholangitis: Interim results from the open-label extension of the ELATIVE® trial up to 3 years

Conference Reports for NATAP

The Liver Meeting
AASLD 2024
Nov 15-19,
San Diego, CA


Long-term efficacy and safety of elafibranor in primary biliary cholangitis: Interim results from the open-label extension of the ELATIVE® trial up to 3 years

	AASLD 2024 The Liver Meeting® \| November 15-19, 2024 \| San Diego, CA, USA.